Faropenem (CAS 106560-14-9)

Faropenem, a member of the carbapenem class of antibiotics, has garnered considerable interest in scientific research due to its potent antimicrobial activity and unique mechanism of action. It inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), particularly PBP2, disrupting the cross-linking of peptidoglycan strands and ultimately leading to bacterial cell death. Unlike other carbapenems, faropenem exhibits enhanced stability against certain β-lactamases, including class A and class C enzymes, which are common mechanisms of bacterial resistance. In research, faropenem has been extensively studied to explore its efficacy against various bacterial pathogens, including Gram-positive and Gram-negative bacteria. Studies have investigated its spectrum of activity, pharmacokinetic properties, and potential applications in the treatment of multidrug-resistant infections. Additionally, faropenem has been evaluated in combination therapy regimens to enhance its antimicrobial efficacy and combat emerging resistance mechanisms. Furthermore, research has focused on the development of novel formulations and delivery systems to improve its bioavailability and tissue distribution, aiming to optimize its potential. Overall, the potent antimicrobial activity and unique resistance profile of faropenem make it a valuable tool in research aimed at combating bacterial infections and understanding the mechanisms of antibiotic resistance.